Rothschild Investment LLC’s Revance Therapeutics, Inc. RVNC Stock Holding History

Rothschild Investment LLC’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-170	Closed	-$517	–	3115
2024 Q4	$517	Sell	170 -75	-31%	-$327	﹤0.01%	2523
2024 Q3	$1.27K	Buy	245 +175	+250%	+$870	﹤0.01%	1991
2024 Q2	$180	Hold	70	–	–	﹤0.01%	2524
2024 Q1	$344	Hold	70	–	–	﹤0.01%	1500
2023 Q4	$615	Buy	+70	New	+$574	﹤0.01%	1218

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Rothschild Investment LLC's RVNC Position: Q1 2025 in Review

Rothschild Investment LLC sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 170 shares — an estimated $517 sold.

Rothschild Investment LLC first reported a position in RVNC in Q4 2023 and held it in 5 quarters. The position peaked at $1.27K in Q3 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Rothschild Investment LLC reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Rothschild Investment LLC sold 170 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $517.
Rothschild Investment LLC first reported a position in Revance Therapeutics, Inc. in Q4 2023 and held it in 5 quarters.
Rothschild Investment LLC's Revance Therapeutics, Inc. position peaked at $1.27K in Q3 2024.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Rothschild Investment LLC's 13F filing for Q1 2025, filed 8 Apr 2025.